择期全膝关节置换静脉血栓预防策略的系统综述与网络荟萃分析
该研究通过系统综述与贝叶斯网络荟萃分析25项随机对照试验,评估择期全膝关节置换患者静脉血栓栓塞预防策略的相对疗效与安全性。肺栓塞和主要出血结局不确定性高,无法得出明确结论。
要点
- 标准预防剂量低分子肝素(28-35天)在肺栓塞网络排名第一,但结果高度不确定。
- 低预防剂量低分子肝素(10-14天)在主要出血网络排名第一,但结果高度不确定。
核心结论
- 在择期全膝关节置换人群中,单一预防策略比联合策略更有效预防深静脉血栓,利伐沙班最有效。
- 肺栓塞和主要出血的荟萃分析结果不确定,除生物学合理性外无法得出明确结论。
研究设计与样本
- 系统综述与贝叶斯网络荟萃分析,纳入25项随机对照试验。
- 深静脉血栓网络纳入23项试验(19种干预;n=15 028),肺栓塞网络纳入12项(13种干预;n=15 555),主要出血网络纳入19项(11种干预;n=19 797)。
- 检索Cochrane Library(CENTRAL)、Embase和Medline,最后检索日期为2017年6月19日。
- 计算与无预防相比的相对风险(RR;95%可信区间[95%CrI])、中位排名及成为最佳干预的概率。
主要发现
- 偏倚风险范围从极低到高。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hospital-associated venous thromboembolism is a major patient safety concern. Provision of prophylaxis to patients admitted for elective total knee replacement surgery has been proposed as an effective strategy to reduce the incidence of venous thromboembolism. We aimed to assess the relative efficacy and safety of all available prophylaxis strategies in this setting. METHODS: We did a systematic review and Bayesian network meta-analyses of randomised controlled trials to assess the relative efficacy and safety of venous thromboembolism prophylaxis strategies and to populate an economic model that assessed the cost-effectiveness of these strategies and informed the updated National Institute for Health and Care Excellence (NICE) guideline recommendations for patients undergoing elective total knee replacement surgery. The Cochrane Library (CENTRAL), Embase, and Medline were last searched on June 19, 2017, with key terms relating to the population (venous thromboembolism and total knee replacement) and the interventions compared, including available pharmacological and mechanical interventions. Outcomes of interest were deep vein thrombosis (symptomatic and asymptomatic), pulmonary embolism, and major bleeding. Risk of bias was assessed, and relevant data extracted from the included randomised controlled trials for the network meta-analyses. Relative risks (RR; with 95% credible intervals [95% CrI]) compared to no prophylaxis, median ranks (with 95% CrI), and the probability of being the best intervention were calculated. The study was done in accordance with PRISMA guidelines. FINDINGS: 25 randomised controlled trials were included in the network meta-analyses. 23 trials (19 interventions; n=15 028) were included in the deep vein thrombosis network, 12 in the pulmonary embolism network (13 interventions; n=15 555), and 19 in the major bleeding network (11 interventions; n=19 797). Risk of bias ranged from very low to high. Rivaroxaban ranked first for prevention of deep vein thrombosis (RR 0·12 [95% CrI 0·06-0·22]). Low molecular weight heparin (LMWH; standard prophylactic dose, 28-35 days) ranked first in the pulmonary embolism network (RR 0·02 [95% CrI 0·00-3·86]) and LMWH (low prophylactic dose, 10-14 days) ranked first in the major bleeding network (odds ratio 0·08 [95% CrI 0·00-1·76]), but the results for pulmonary embolism and major bleeding are highly uncertain. INTERPRETATION: Single prophylaxis strategies are more effective in prevention of deep vein thrombosis in the elective total knee replacement population than combination strategies, with rivaroxaban being the most effective. The results of the pulmonary embolism and major bleeding meta-analyses are uncertain and no clear conclusion can be made other than what is biologically plausible (eg, that no prophylaxis and mechanical prophylaxis strategies should have the lowest risk of major bleeding). FUNDING: National Institute for Health and Care Excellence.
引用
- Lewis S, Glen J, Dawoud D, et al. Venous thromboembolism prophylaxis strategies for people undergoing elective total knee replacement: a systematic review and network meta-analysis. Lancet Haematol. 2019. PMID: 31444124. doi:10.1016/S2352-3026(19)30155-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。